Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D9ICV2
|
|||
Drug Name |
TAK-500
|
|||
Drug Type |
Antibody drug conjugate
|
|||
Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Takeda
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Stimulator of interferon genes protein (TMEM173) | Target Info | Agonist | [1] |
KEGG Pathway | NOD-like receptor signaling pathway | |||
RIG-I-like receptor signaling pathway | ||||
Cytosolic DNA-sensing pathway | ||||
Human cytomegalovirus infection | ||||
Herpes simplex virus 1 infection | ||||
Human immunodeficiency virus 1 infection |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.